Insider · CIK 0001261506

DAWES KAREN A

Reports to the SEC for 5 companies · GERMANTOWN, MD

sec.gov

Transactions

Companies

Filings

CIK

0001261506

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-09	BRNSBarinthus Biotherapeutics plc. · Share Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−19.2K sh	—	—	0
2026-09-09	BRNSBarinthus Biotherapeutics plc. · Share Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20.2K sh	—	—	0
2026-09-09	BRNSBarinthus Biotherapeutics plc. · Share Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−19.5K sh	—	—	0
2026-09-09	BRNSBarinthus Biotherapeutics plc. · Share Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−34.3K sh	—	—	0
2026-09-09	BRNSBarinthus Biotherapeutics plc.D Disposition to Issuer	Director	DDisposition to Issuer	−1,700 sh	—	—	0
2026-09-09	BRNSBarinthus Biotherapeutics plc. · Share Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−18.6K sh	—	—	0
2026-05-14	RGENREPLIGEN CORPA Award	Director	AAward	+995 sh	—	—	92,816
2026-05-14	RGENREPLIGEN CORP · Stock Option (Right to Buy)A Award	Director	AAward	+2,239 sh	—	—	2,239
2025-12-17	RGENREPLIGEN CORPS Sale	Director	SSale	−275 sh	$161.00	−$44.3K	91,821
2025-06-10	BRNSBarinthus Biotherapeutics plc. · Share Option (Right to Buy)A Award	Director	AAward	+20.2K sh	—	—	20,174
2025-05-15	RGENREPLIGEN CORP · Stock Option (Right to Buy)A Award	Director	AAward	+1,800 sh	—	—	1,800
2025-05-15	RGENREPLIGEN CORPA Award	Director	AAward	+973 sh	—	—	92,096
2024-06-14	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	+2,953 sh	—	—	0
2024-06-14	RGENREPLIGEN CORPM Exercise/Conversion	Director	MExercise/Conversion	+2,953 sh	$67.71	+$200K	88,170
2024-05-16	RGENREPLIGEN CORP · Stock Option (Right to Buy)A Award	Director	AAward	+1,576 sh	—	—	1,576
2024-05-16	RGENREPLIGEN CORPA Award	Director	AAward	+803 sh	—	—	88,170
2024-05-10	BRNSBarinthus Biotherapeutics plc. · Share Option (Right to Buy)A Award	Director	AAward	+19.5K sh	—	—	19,516
2024-02-27	RGENREPLIGEN CORPM Exercise/Conversion	Director	MExercise/Conversion	+4,626 sh	$42.07	+$195K	88,367
2024-02-27	RGENREPLIGEN CORPS Sale	Director	SSale	−1,000 sh	$193.35	−$193K	87,367
2024-02-27	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	+4,626 sh	—	—	0
2023-08-29	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	+7,392 sh	—	—	0
2023-08-29	RGENREPLIGEN CORPS Sale	Director	SSale	−850 sh	$171.38	−$146K	83,741
2023-08-29	RGENREPLIGEN CORPM Exercise/Conversion	Director	MExercise/Conversion	+7,392 sh	$18.12	+$134K	84,591
2023-05-18	RGENREPLIGEN CORPA Award	Director	AAward	+798 sh	—	—	77,199
2023-05-18	RGENREPLIGEN CORP · Stock Option (Right to Buy)A Award	Director	AAward	+1,730 sh	—	—	1,730
2023-05-11	BRNSBarinthus Biotherapeutics plc. · Share Option (Right to Buy)A Award	Director	AAward	+19.2K sh	—	—	19,197
2022-09-09	RGENREPLIGEN CORPS Sale	Director	SSale	−775 sh	$227.17	−$176K	76,401
2022-06-15	BRNSBarinthus Biotherapeutics plc. · Share Option (Right to Buy)A Award	Director	AAward	+18.6K sh	—	—	18,604
2022-05-26	RGENREPLIGEN CORP · Stock Option (Right to Buy)A Award	Director	AAward	+1,565 sh	—	—	1,565
2022-05-26	RGENREPLIGEN CORPA Award	Director	AAward	+644 sh	—	—	77,176
2022-05-25	RGENREPLIGEN CORPS Sale	Director	SSale	−7,677 sh	$150.19	−$1.15M	80,994
2022-05-25	RGENREPLIGEN CORPS Sale	Director	SSale	−2,576 sh	$149.18	−$384K	88,671
2022-05-25	RGENREPLIGEN CORPS Sale	Director	SSale	−1,845 sh	$151.14	−$279K	79,149
2022-05-25	RGENREPLIGEN CORPS Sale	Director	SSale	−742 sh	$152.84	−$113K	76,532
2022-05-25	RGENREPLIGEN CORPS Sale	Director	SSale	−1,875 sh	$152.14	−$285K	77,274
2021-11-10	RGENREPLIGEN CORPS Sale	Director	SSale	−486 sh	$266.72	−$130K	91,865
2021-11-10	RGENREPLIGEN CORPS Sale	Director	SSale	−336 sh	$264.21	−$88.8K	92,839
2021-11-10	RGENREPLIGEN CORPS Sale	Director	SSale	−488 sh	$265.27	−$129K	92,351
2021-11-10	RGENREPLIGEN CORPS Sale	Director	SSale	−349 sh	$267.75	−$93.4K	91,516
2021-11-10	RGENREPLIGEN CORPS Sale	Director	SSale	−1,119 sh	$263.23	−$295K	93,175
2021-11-10	RGENREPLIGEN CORPS Sale	Director	SSale	−255 sh	$269.94	−$68.8K	91,261
2021-11-10	RGENREPLIGEN CORPM Exercise/Conversion	Director	MExercise/Conversion	−4,783 sh	$26.12	−$125K	96,030
2021-11-10	RGENREPLIGEN CORPS Sale	Director	SSale	−462 sh	$259.75	−$120K	95,568
2021-11-10	RGENREPLIGEN CORPS Sale	Director	SSale	−14 sh	$271.28	−$3,797.92	91,247
2021-11-10	RGENREPLIGEN CORPS Sale	Director	SSale	−236 sh	$261.10	−$61.6K	95,332
2021-11-10	RGENREPLIGEN CORPS Sale	Director	SSale	−1,038 sh	$262.28	−$272K	94,294
2021-11-10	RGENREPLIGEN CORP · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	+4,783 sh	—	—	0
2021-11-02	RGENREPLIGEN CORPS Sale	Director	SSale	−64 sh	$299.02	−$19.1K	93,583
2021-11-02	RGENREPLIGEN CORPS Sale	Director	SSale	−251 sh	$301.20	−$75.6K	93,332
2021-11-02	RGENREPLIGEN CORPS Sale	Director	SSale	−446 sh	$301.97	−$135K	92,886

Recent filings

Accepted (ET)
Sep 94
DAWES KAREN A0001104659-26-106323
SEC(opens sec.gov)
May 184
DAWES KAREN A0001193125-26-228884
SEC(opens sec.gov)
Dec 184
DAWES KAREN A0001193125-25-324912
SEC(opens sec.gov)
Jun 114
DAWES KAREN A0001828185-25-000039
SEC(opens sec.gov)
May 194
DAWES KAREN A0000950170-25-074251
SEC(opens sec.gov)
Jun 144
DAWES KAREN A0000950170-24-073829
SEC(opens sec.gov)
May 204
DAWES KAREN A0000950170-24-062599
SEC(opens sec.gov)
May 144
DAWES KAREN A0001828185-24-000058
SEC(opens sec.gov)
Feb 284
DAWES KAREN A0000950170-24-022581
SEC(opens sec.gov)

Companies

Address

C/O BARINTHUS BIOTHERAPEUTICS PLC 20400 CENTURY BOULEVARD

GERMANTOWN, MD, 20874